Clinical Trials Logo

Clinical Trial Summary

This study is a prospective cohort study of children diagnosed with primary immunodeficiency disease (PID). The aim is to investigate the clinical characteristics and prognosis of PID in Chinese children.


Clinical Trial Description

Primary immunodeficiency disease (PID) is a group of rare and fatal disease. However, the research about clinical characteristics, treatment, management and prognosis of Chinese children with PID is still not perfect and there is no basic and large database. Therefore, this study is conducted, in order to set up a complete database and long term follow up of Chinese children with PID, and establish foundations for basic research and precise medicine.

This study is divided into two parts. In part one, pediatric patients with PID in the past 10 years will be collected retrospectively by review medical records from these centers, and investigate the clinical features and prognosis. In part two, all new cases with suspected PID will be collected. Clinical symptoms, physical examination, blood tests, and humoral and cellular immune functions will be detected. Gene tests would be done when necessary to confirm the diagnosis. Then follow up at 6-moth, 1-year, 2-year, 3-year, 4-year and 5-year respectively. The trial will be completed in 60 months. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03252548
Study type Observational
Source Beijing Children's Hospital
Contact baoping xu, MD,PhD
Phone 861059616308
Email xubaopingbch@163.com
Status Not yet recruiting
Phase N/A
Start date January 2018
Completion date August 2022

See also
  Status Clinical Trial Phase
Recruiting NCT03677557 - Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment Phase 4
Completed NCT02810444 - Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID Phase 3
Enrolling by invitation NCT01150240 - Clinical and Laboratory Online Patient- and Research Database for Primary Immunodeficiencies in Switzerland N/A
Recruiting NCT04944979 - Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10) Phase 3
Completed NCT02627300 - Study of Octanorm Subcutaneous IG in Patients With Primary Immunodeficiency Diseases Who Have Completed the SCGAM-01 Trial Phase 3
Completed NCT03961009 - Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients Phase 3
Completed NCT04842643 - An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency Disease Phase 3
Not yet recruiting NCT06089122 - Efficacy, Safety, and Pharmacokinetics of Shu Yang IVIG Phase 3
Not yet recruiting NCT06150833 - Efficacy and Safety and Pharmacokinetics of Boya IVIG Phase 3